Skip to main content
Top
Published in: Antimicrobial Resistance & Infection Control 1/2024

Open Access 01-12-2024 | Pseudomonas Aeruginosa | Review

Prevalence of meropenem-resistant Pseudomonas Aeruginosa in Ethiopia: a systematic review and meta‑analysis

Authors: Mengistie Yirsaw Gobezie, Minimize Hassen, Nuhamin Alemayehu Tesfaye, Tewodros Solomon, Mulat Belete Demessie, Tesfaye Dessale Kassa, Teklehaimanot Fentie Wendie, Abel Andualem, Ermiyas Alemayehu, Yaschilal Muche Belayneh

Published in: Antimicrobial Resistance & Infection Control | Issue 1/2024

Login to get access

Abstract

Introduction

Antimicrobial resistance (AMR) is a pressing global health concern, particularly pronounced in low-resource settings. In Ethiopia, the escalating prevalence of carbapenem-resistant Pseudomonas aeruginosa (P. aeruginosa) poses a substantial threat to public health.

Methods

A comprehensive search of databases, including PubMed, Scopus, Embase, Hinari, and Google Scholar, identified relevant studies. Inclusion criteria encompassed observational studies reporting the prevalence of meropenem-resistant P. aeruginosa in Ethiopia. Quality assessment utilized JBI checklists. A random-effects meta-analysis pooled data on study characteristics and prevalence estimates, with subsequent subgroup and sensitivity analyses. Publication bias was assessed graphically and statistically.

Results

Out of 433 studies, nineteen, comprising a total sample of 11,131, met inclusion criteria. The pooled prevalence of meropenem-resistant P. aeruginosa was 15% (95% CI: 10–21%). Significant heterogeneity (I2 = 83.6%) was observed, with the number of P. aeruginosa isolates identified as the primary source of heterogeneity (p = 0.127). Subgroup analysis by infection source revealed a higher prevalence in hospital-acquired infections (28%, 95% CI: 10, 46) compared to community settings (6%, 95% CI: 2, 11). Geographic based subgroup analysis indicated the highest prevalence in the Amhara region (23%, 95% CI: 8, 38), followed by Addis Ababa (21%, 95% CI: 11, 32), and lower prevalence in the Oromia region (7%, 95% CI: 4, 19). Wound samples exhibited the highest resistance (25%, 95% CI: 25, 78), while sputum samples showed the lowest prevalence. Publication bias, identified through funnel plot examination and Egger’s regression test (p < 0.001), execution of trim and fill analysis resulted in an adjusted pooled prevalence of (3.7%, 95% CI: 2.3, 9.6).

Conclusion

The noteworthy prevalence of meropenem resistance among P. aeruginosa isolates in Ethiopia, particularly in healthcare settings, underscores the urgency of implementing strict infection control practices and antibiotic stewardship. Further research is imperative to address and mitigate the challenges posed by antimicrobial resistance in the country.
Literature
1.
go back to reference Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, Han C, Bisignano C, Rao P, Wool E. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–55.CrossRef Murray CJ, Ikuta KS, Sharara F, Swetschinski L, Aguilar GR, Gray A, Han C, Bisignano C, Rao P, Wool E. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet. 2022;399(10325):629–55.CrossRef
2.
go back to reference World Health Organization. Antimicrobial Resistance in the WHO African Region: a systematic literature review. Antimicrobial resistance in the WHO African Region: a systematic literature review. 2021. World Health Organization. Antimicrobial Resistance in the WHO African Region: a systematic literature review. Antimicrobial resistance in the WHO African Region: a systematic literature review. 2021.
3.
go back to reference Pier GB. 314 - Pseudomonas and related gram-negative Bacillary infections. In: Goldman L, Schafer AI, editors. Goldman’s Cecil Medicine (Twenty Fourth Edition). Philadelphia: W.B. Saunders; 2012. pp. 1877–81. Pier GB. 314 - Pseudomonas and related gram-negative Bacillary infections. In: Goldman L, Schafer AI, editors. Goldman’s Cecil Medicine (Twenty Fourth Edition). Philadelphia: W.B. Saunders; 2012. pp. 1877–81.
4.
go back to reference Smith RS, Iglewski BH. P. Aeruginosa quorum-sensing systems and virulence. Curr Opin Microbiol. 2003;6(1):56–60.PubMedCrossRef Smith RS, Iglewski BH. P. Aeruginosa quorum-sensing systems and virulence. Curr Opin Microbiol. 2003;6(1):56–60.PubMedCrossRef
5.
go back to reference Gómez MI, Prince A. Opportunistic infections in lung disease: Pseudomonas infections in cystic fibrosis. Curr Opin Pharmacol. 2007;7(3):244–51.PubMedCrossRef Gómez MI, Prince A. Opportunistic infections in lung disease: Pseudomonas infections in cystic fibrosis. Curr Opin Pharmacol. 2007;7(3):244–51.PubMedCrossRef
6.
go back to reference Robertson LA, Cornelisse R, De Vos P, Hadioetomo R, Kuenen JG. Aerobic denitrification in various heterotrophic nitrifiers. Antonie Van Leeuwenhoek. 1989;56(4):289–99.PubMedCrossRef Robertson LA, Cornelisse R, De Vos P, Hadioetomo R, Kuenen JG. Aerobic denitrification in various heterotrophic nitrifiers. Antonie Van Leeuwenhoek. 1989;56(4):289–99.PubMedCrossRef
7.
go back to reference Khaledi A, Elahifar O, Vazini H, Alikhani MY, Bahrami A, Esmaeili D, Ghazvini K. Increasing trend of imipenem-resistance among acinetobacter baumannii isolated from Hospital Acquired Pneumonia in Northeast of Iran. Avicenna J Clin Microbiol Infect. 2017;4(3):45454.CrossRef Khaledi A, Elahifar O, Vazini H, Alikhani MY, Bahrami A, Esmaeili D, Ghazvini K. Increasing trend of imipenem-resistance among acinetobacter baumannii isolated from Hospital Acquired Pneumonia in Northeast of Iran. Avicenna J Clin Microbiol Infect. 2017;4(3):45454.CrossRef
8.
go back to reference Makeri D, Odoki M, Eilu E, Agwu E. Update on prevalence and antimicrobial resistance of Staphylococcus aureus and Pseudomonas aeruginosa isolated from diabetic foot ulcers in Africa: a systematic review and meta-analysis. Bull Natl Res Centre. 2023;47(1):145.CrossRef Makeri D, Odoki M, Eilu E, Agwu E. Update on prevalence and antimicrobial resistance of Staphylococcus aureus and Pseudomonas aeruginosa isolated from diabetic foot ulcers in Africa: a systematic review and meta-analysis. Bull Natl Res Centre. 2023;47(1):145.CrossRef
10.
go back to reference Esmaeili D, Daymad SF, Neshani A, Rashki S, Marzhoseyni Z, Khaledi A. Alerting prevalence of MBLs producing Pseudomonas aeruginosa isolates. Gene Rep. 2019;16:100460.CrossRef Esmaeili D, Daymad SF, Neshani A, Rashki S, Marzhoseyni Z, Khaledi A. Alerting prevalence of MBLs producing Pseudomonas aeruginosa isolates. Gene Rep. 2019;16:100460.CrossRef
11.
go back to reference Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev. 2009;22(4):582–610.PubMedPubMedCentralCrossRef Lister PD, Wolter DJ, Hanson ND. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin Microbiol Rev. 2009;22(4):582–610.PubMedPubMedCentralCrossRef
12.
go back to reference Omulo S, Oluka M, Ombajo L, Osoro E, Kinuthia R, Guantai A, Ndegwa L, Verani J, Opanga S, Wesangula E, Nyakiba J, Makori J, Kwobah C, Sugut W, Osuka H, Njenga MK, Call D, Palmer GH, VanderEnde D, Luvsansharav U-O. Point-prevalence surveys of antibiotic use at three large public hospitals in Kenya. Infect Control Hosp Epidemiol. 2020;41(S1):s353–4.CrossRef Omulo S, Oluka M, Ombajo L, Osoro E, Kinuthia R, Guantai A, Ndegwa L, Verani J, Opanga S, Wesangula E, Nyakiba J, Makori J, Kwobah C, Sugut W, Osuka H, Njenga MK, Call D, Palmer GH, VanderEnde D, Luvsansharav U-O. Point-prevalence surveys of antibiotic use at three large public hospitals in Kenya. Infect Control Hosp Epidemiol. 2020;41(S1):s353–4.CrossRef
13.
go back to reference Tadesse BT, Ashley EA, Ongarello S, Havumaki J, Wijegoonewardena M, González IJ, Dittrich S. Antimicrobial resistance in Africa: a systematic review. BMC Infect Dis. 2017;17(1):616.PubMedPubMedCentralCrossRef Tadesse BT, Ashley EA, Ongarello S, Havumaki J, Wijegoonewardena M, González IJ, Dittrich S. Antimicrobial resistance in Africa: a systematic review. BMC Infect Dis. 2017;17(1):616.PubMedPubMedCentralCrossRef
14.
go back to reference Addis T, Araya S, Desta K. Occurrence of multiple, extensive and pan drug-resistant Pseudomonas aeruginosa and Carbapenemase Production from Presumptive isolates stored in a biobank at Ethiopian public health institute. Infect Drug Resist. 2021;14:3609–18.PubMedPubMedCentralCrossRef Addis T, Araya S, Desta K. Occurrence of multiple, extensive and pan drug-resistant Pseudomonas aeruginosa and Carbapenemase Production from Presumptive isolates stored in a biobank at Ethiopian public health institute. Infect Drug Resist. 2021;14:3609–18.PubMedPubMedCentralCrossRef
15.
go back to reference Ayobami O, Willrich N, Harder T, Okeke IN, Eckmanns T, Markwart R. The incidence and prevalence of hospital-acquired (carbapenem-resistant) Acinetobacter baumannii in Europe, Eastern Mediterranean and Africa: a systematic review and meta-analysis. Emerg Microbes Infect. 2019;8(1):1747–59.PubMedPubMedCentralCrossRef Ayobami O, Willrich N, Harder T, Okeke IN, Eckmanns T, Markwart R. The incidence and prevalence of hospital-acquired (carbapenem-resistant) Acinetobacter baumannii in Europe, Eastern Mediterranean and Africa: a systematic review and meta-analysis. Emerg Microbes Infect. 2019;8(1):1747–59.PubMedPubMedCentralCrossRef
16.
go back to reference Anane AY, Apalata T, Vasaikar S, Okuthe GE, Songca S. Prevalence and molecular analysis of multidrug-resistant Acinetobacter baumannii in the extra-hospital environment in Mthatha, South Africa. Braz J Infect Dis. 2019;23(6):371–80.CrossRef Anane AY, Apalata T, Vasaikar S, Okuthe GE, Songca S. Prevalence and molecular analysis of multidrug-resistant Acinetobacter baumannii in the extra-hospital environment in Mthatha, South Africa. Braz J Infect Dis. 2019;23(6):371–80.CrossRef
17.
go back to reference Acar A, Karaahmetoğlu G, Akalın H, Altay AF. Pooled prevalence and trends of antimicrobial resistance in Pseudomonas aeruginosa clinical isolates over the past 10 years in Turkey: a meta-analysis. J Global Antimicrob Resist. 2019;18:64–70.CrossRef Acar A, Karaahmetoğlu G, Akalın H, Altay AF. Pooled prevalence and trends of antimicrobial resistance in Pseudomonas aeruginosa clinical isolates over the past 10 years in Turkey: a meta-analysis. J Global Antimicrob Resist. 2019;18:64–70.CrossRef
18.
go back to reference Lowings M, Ehlers MM, Dreyer AW, Kock MM. High prevalence of oxacillinases in clinical multidrug-resistant Acinetobacter baumannii isolates from the tshwane region, South Africa - an update. BMC Infect Dis. 2015;15:521.PubMedPubMedCentralCrossRef Lowings M, Ehlers MM, Dreyer AW, Kock MM. High prevalence of oxacillinases in clinical multidrug-resistant Acinetobacter baumannii isolates from the tshwane region, South Africa - an update. BMC Infect Dis. 2015;15:521.PubMedPubMedCentralCrossRef
19.
go back to reference Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906.PubMedCrossRef Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Int J Surg. 2021;88:105906.PubMedCrossRef
20.
go back to reference Gotschall T. EndNote 20 desktop version. J Med Libr Association: JMLA. 2021;109(3):520. Gotschall T. EndNote 20 desktop version. J Med Libr Association: JMLA. 2021;109(3):520.
21.
go back to reference Joanna Briggs Institute. JBI critical appraisal checklist for studies reporting prevalence data. Adelaide: University of Adelaide. 2017. Joanna Briggs Institute. JBI critical appraisal checklist for studies reporting prevalence data. Adelaide: University of Adelaide. 2017.
22.
go back to reference DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 2007;28(2):105–14.PubMedCrossRef DerSimonian R, Kacker R. Random-effects model for meta-analysis of clinical trials: an update. Contemp Clin Trials. 2007;28(2):105–14.PubMedCrossRef
24.
go back to reference Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295(6):676–80.PubMedCrossRef Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295(6):676–80.PubMedCrossRef
25.
go back to reference StataCorp. Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC. 2021. StataCorp. Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC. 2021.
26.
go back to reference Abda EM, Adugna Z, Assefa A. Elevated level of imipenem-resistant gram-negative bacteria isolated from patients attending health centers in North Gondar, Ethiopia. Infect Drug Resist. 2020;13:4509–17.PubMedPubMedCentralCrossRef Abda EM, Adugna Z, Assefa A. Elevated level of imipenem-resistant gram-negative bacteria isolated from patients attending health centers in North Gondar, Ethiopia. Infect Drug Resist. 2020;13:4509–17.PubMedPubMedCentralCrossRef
27.
go back to reference Alebel M, Mekonnen F, Mulu W. Extended-spectrum β-lactamase and carbapenemase producing gram-negative bacilli infections among patients in intensive care units of felegehiwot referral hospital: a prospective cross-sectional study. Infect Drug Resist. 2021;14:391–405.PubMedPubMedCentralCrossRef Alebel M, Mekonnen F, Mulu W. Extended-spectrum β-lactamase and carbapenemase producing gram-negative bacilli infections among patients in intensive care units of felegehiwot referral hospital: a prospective cross-sectional study. Infect Drug Resist. 2021;14:391–405.PubMedPubMedCentralCrossRef
28.
go back to reference Legese MH, Asrat D, Swedberg G, Hasan B, Mekasha A, Getahun T, Worku M, Shimber ET, Getahun S, Ayalew T. Sepsis: emerging pathogens and antimicrobial resistance in Ethiopian referral hospitals. Antimicrob Resist Infect Control. 2022;11(1):83.PubMedPubMedCentralCrossRef Legese MH, Asrat D, Swedberg G, Hasan B, Mekasha A, Getahun T, Worku M, Shimber ET, Getahun S, Ayalew T. Sepsis: emerging pathogens and antimicrobial resistance in Ethiopian referral hospitals. Antimicrob Resist Infect Control. 2022;11(1):83.PubMedPubMedCentralCrossRef
29.
go back to reference Mekonnen H, Seid A, Fenta GM, Gebrecherkos T. Antimicrobial resistance profiles and associated factors of Acinetobacter and Pseudomonas aeruginosa nosocomial infection among patients admitted at Dessie comprehensive specialized hospital, NorthEast Ethiopia. A cross-sectional study. Plos One. 2021;16:e0257272(11 November).PubMedPubMedCentralCrossRef Mekonnen H, Seid A, Fenta GM, Gebrecherkos T. Antimicrobial resistance profiles and associated factors of Acinetobacter and Pseudomonas aeruginosa nosocomial infection among patients admitted at Dessie comprehensive specialized hospital, NorthEast Ethiopia. A cross-sectional study. Plos One. 2021;16:e0257272(11 November).PubMedPubMedCentralCrossRef
30.
go back to reference Motbainor H, Bereded F, Mulu W. Multi-drug resistance of blood stream, urinary tract and surgical site nosocomial infections of Acinetobacter baumannii and Pseudomonas aeruginosa among patients hospitalized at Felegehiwot referral hospital, Northwest Ethiopia: a cross-sectional study. BMC Infect Dis. 2020;20(1):92.PubMedPubMedCentralCrossRef Motbainor H, Bereded F, Mulu W. Multi-drug resistance of blood stream, urinary tract and surgical site nosocomial infections of Acinetobacter baumannii and Pseudomonas aeruginosa among patients hospitalized at Felegehiwot referral hospital, Northwest Ethiopia: a cross-sectional study. BMC Infect Dis. 2020;20(1):92.PubMedPubMedCentralCrossRef
31.
go back to reference Tilahun M, Multi-Drug R, Profile. Prevalence of extended-spectrum beta-lactamase and carbapenemase-producing Gram negative Bacilli among admitted patients after surgery with suspected of Surgical Site nosocomial infection North East Ethiopia. Infect Drug Resist. 2022;15:3949–65.PubMedPubMedCentralCrossRef Tilahun M, Multi-Drug R, Profile. Prevalence of extended-spectrum beta-lactamase and carbapenemase-producing Gram negative Bacilli among admitted patients after surgery with suspected of Surgical Site nosocomial infection North East Ethiopia. Infect Drug Resist. 2022;15:3949–65.PubMedPubMedCentralCrossRef
32.
go back to reference Tilahun M, Gedefie A, Bisetegn H, Debash H. Emergence of high prevalence of extended-spectrum beta-lactamase and carbapenemase producing Acinetobacter species and Pseudomonas aeruginosa among hospitalized patients at Dessie Comprehensive Specialized Hospital. North-East Ethiopia Infect Drug Resist. 2022;15:895–911.PubMedCrossRef Tilahun M, Gedefie A, Bisetegn H, Debash H. Emergence of high prevalence of extended-spectrum beta-lactamase and carbapenemase producing Acinetobacter species and Pseudomonas aeruginosa among hospitalized patients at Dessie Comprehensive Specialized Hospital. North-East Ethiopia Infect Drug Resist. 2022;15:895–911.PubMedCrossRef
33.
34.
go back to reference Gashaw M, Berhane M, Bekele S, Kibru G, Teshager L, Yilma Y, Ahmed Y, Fentahun N, Assefa H, Wieser A, Gudina EK, Ali S. Emergence of high drug resistant bacterial isolates from patients with health care associated infections at Jimma University medical center: a cross sectional study. Antimicrob Resist Infect Control. 2018;7(1):138.PubMedPubMedCentralCrossRef Gashaw M, Berhane M, Bekele S, Kibru G, Teshager L, Yilma Y, Ahmed Y, Fentahun N, Assefa H, Wieser A, Gudina EK, Ali S. Emergence of high drug resistant bacterial isolates from patients with health care associated infections at Jimma University medical center: a cross sectional study. Antimicrob Resist Infect Control. 2018;7(1):138.PubMedPubMedCentralCrossRef
35.
go back to reference Mussema A, Beyene G, Gashaw M. Bacterial isolates and antibacterial resistance patterns in a patient with acute exacerbation of chronic obstructive pulmonary disease in a tertiary teaching hospital, Southwest Ethiopia. CanadianJournal of Infectious Diseases and Medical Microbiology. 2022;2022:9709253.PubMed Mussema A, Beyene G, Gashaw M. Bacterial isolates and antibacterial resistance patterns in a patient with acute exacerbation of chronic obstructive pulmonary disease in a tertiary teaching hospital, Southwest Ethiopia. CanadianJournal of Infectious Diseases and Medical Microbiology. 2022;2022:9709253.PubMed
36.
go back to reference Sewunet T, Asrat D, Woldeamanuel Y, Aseffa A, Giske CG. Molecular epidemiology and antimicrobial susceptibility of Pseudomonas spp. and Acinetobacter spp. from clinical samples at Jimma medical center Ethiopia. Front Microbiol. 2022;13:951857.PubMedPubMedCentralCrossRef Sewunet T, Asrat D, Woldeamanuel Y, Aseffa A, Giske CG. Molecular epidemiology and antimicrobial susceptibility of Pseudomonas spp. and Acinetobacter spp. from clinical samples at Jimma medical center Ethiopia. Front Microbiol. 2022;13:951857.PubMedPubMedCentralCrossRef
37.
go back to reference Abayneh M, Asnake M, Muleta D, Simieneh A. Assessment of bacterial profiles and antimicrobial susceptibility pattern of isolates among patients diagnosed with Surgical Site infections at Mizan-Tepi University Teaching Hospital, Southwest Ethiopia: a prospective Observational Cohort Study. Infect Drug Resist. 2022;15:1807–19.PubMedPubMedCentralCrossRef Abayneh M, Asnake M, Muleta D, Simieneh A. Assessment of bacterial profiles and antimicrobial susceptibility pattern of isolates among patients diagnosed with Surgical Site infections at Mizan-Tepi University Teaching Hospital, Southwest Ethiopia: a prospective Observational Cohort Study. Infect Drug Resist. 2022;15:1807–19.PubMedPubMedCentralCrossRef
38.
go back to reference Alemayehu T, Asnake S, Tadesse B, Azerefegn E, Mitiku E, Agegnehu A, Nigussie N, H/Mariam T, Desta M. Phenotypic detection of Carbapenem-resistant gram-negative Bacilli from a clinical specimen in Sidama, Ethiopia: a cross-sectional study. Infect Drug Resist. 2021;14:369–80.PubMedPubMedCentralCrossRef Alemayehu T, Asnake S, Tadesse B, Azerefegn E, Mitiku E, Agegnehu A, Nigussie N, H/Mariam T, Desta M. Phenotypic detection of Carbapenem-resistant gram-negative Bacilli from a clinical specimen in Sidama, Ethiopia: a cross-sectional study. Infect Drug Resist. 2021;14:369–80.PubMedPubMedCentralCrossRef
39.
go back to reference Mitiku A, Aklilu A, Tsalla T, Woldemariam M, Manilal A, Biru M. Magnitude and antimicrobial susceptibility profiles of Gram-negative bacterial isolates among patients suspected of urinary tract infections in Arba Minch General Hospital, southern Ethiopia. Plos One. 2022;17:e0279887 (12 December).PubMedPubMedCentralCrossRef Mitiku A, Aklilu A, Tsalla T, Woldemariam M, Manilal A, Biru M. Magnitude and antimicrobial susceptibility profiles of Gram-negative bacterial isolates among patients suspected of urinary tract infections in Arba Minch General Hospital, southern Ethiopia. Plos One. 2022;17:e0279887 (12 December).PubMedPubMedCentralCrossRef
40.
go back to reference Abdeta A, Bitew A, Fentaw S, Tsige E, Assefa D, Lejisa T, Kefyalew Y, Tigabu E, Evans M. Phenotypic characterization of carbapenem non-susceptible gram-negative bacilli isolated from clinical specimens. Plos One. 2021;16:e0256556 (12 December).PubMedPubMedCentralCrossRef Abdeta A, Bitew A, Fentaw S, Tsige E, Assefa D, Lejisa T, Kefyalew Y, Tigabu E, Evans M. Phenotypic characterization of carbapenem non-susceptible gram-negative bacilli isolated from clinical specimens. Plos One. 2021;16:e0256556 (12 December).PubMedPubMedCentralCrossRef
41.
go back to reference Beshah D, Desta A, Belay G, Abebe T, Gebreselasie S, Sisay Tessema T. Antimicrobial resistance and associated risk factors of Gram-negative bacterial bloodstream infections in Tikur Anbessa Specialized Hospital, Addis Ababa. Infect Drug Resist. 2022;15:5043–59.PubMedPubMedCentralCrossRef Beshah D, Desta A, Belay G, Abebe T, Gebreselasie S, Sisay Tessema T. Antimicrobial resistance and associated risk factors of Gram-negative bacterial bloodstream infections in Tikur Anbessa Specialized Hospital, Addis Ababa. Infect Drug Resist. 2022;15:5043–59.PubMedPubMedCentralCrossRef
42.
go back to reference Beshah D, Desta AF, Woldemichael GB, Belachew EB, Derese SG, Zelelie TZ, Desalegn Z, Tessema TS, Gebreselasie S, Abebe T. High burden of ESBL and carbapenemase-producing gram-negative bacteria in bloodstream infection patients at a tertiary care hospital in Addis Ababa, Ethiopia. Plos One. 2023;18(6):e0287453.PubMedPubMedCentralCrossRef Beshah D, Desta AF, Woldemichael GB, Belachew EB, Derese SG, Zelelie TZ, Desalegn Z, Tessema TS, Gebreselasie S, Abebe T. High burden of ESBL and carbapenemase-producing gram-negative bacteria in bloodstream infection patients at a tertiary care hospital in Addis Ababa, Ethiopia. Plos One. 2023;18(6):e0287453.PubMedPubMedCentralCrossRef
43.
go back to reference Bizuayehu H, Bitew A, Abdeta A, Ebrahim S. Catheter-associated urinary tract infections in adult intensive care units at a selected tertiary hospital, Addis Ababa, Ethiopia. Plos One. 2022;17(3):e0265102.PubMedPubMedCentralCrossRef Bizuayehu H, Bitew A, Abdeta A, Ebrahim S. Catheter-associated urinary tract infections in adult intensive care units at a selected tertiary hospital, Addis Ababa, Ethiopia. Plos One. 2022;17(3):e0265102.PubMedPubMedCentralCrossRef
44.
go back to reference Mekonnen S, Tesfa T, Shume T, Tebeje F, Urgesa K, Weldegebreal F. Bacterial profile, their antibiotic susceptibility pattern, and associated factors of urinary tract infections in children at Hiwot Fana Specialized University Hospital, Eastern Ethiopia. Plos One. 2023;18(4):e0283637.PubMedPubMedCentralCrossRef Mekonnen S, Tesfa T, Shume T, Tebeje F, Urgesa K, Weldegebreal F. Bacterial profile, their antibiotic susceptibility pattern, and associated factors of urinary tract infections in children at Hiwot Fana Specialized University Hospital, Eastern Ethiopia. Plos One. 2023;18(4):e0283637.PubMedPubMedCentralCrossRef
45.
go back to reference Herrera-Espejo S, Del Barrio-Tofiño E, Cebrero-Cangueiro T, López-Causapé C, Álvarez-Marín R, Cisneros JM, Pachón J, Oliver A, Pachón-Ibáñez ME. Carbapenem combinations for infections caused by carbapenemase-producing Pseudomonas aeruginosa: experimental in vitro and in vivo analysis. Antibiotics. 2022;11(9):1212.PubMedPubMedCentralCrossRef Herrera-Espejo S, Del Barrio-Tofiño E, Cebrero-Cangueiro T, López-Causapé C, Álvarez-Marín R, Cisneros JM, Pachón J, Oliver A, Pachón-Ibáñez ME. Carbapenem combinations for infections caused by carbapenemase-producing Pseudomonas aeruginosa: experimental in vitro and in vivo analysis. Antibiotics. 2022;11(9):1212.PubMedPubMedCentralCrossRef
46.
go back to reference Luyt C-E, Aubry A, Lu Q, Micaelo M, Bréchot N, Brossier F, Brisson H, Rouby J-J, Trouillet J-L, Combes A. Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia. Antimicrob Agents Chemother. 2014;58(3):1372–80.PubMedPubMedCentralCrossRef Luyt C-E, Aubry A, Lu Q, Micaelo M, Bréchot N, Brossier F, Brisson H, Rouby J-J, Trouillet J-L, Combes A. Imipenem, meropenem, or doripenem to treat patients with Pseudomonas aeruginosa ventilator-associated pneumonia. Antimicrob Agents Chemother. 2014;58(3):1372–80.PubMedPubMedCentralCrossRef
47.
go back to reference Judd WR, Ratliff PD, Hickson RP, Stephens DM, Kennedy CA. Clinical and economic impact of meropenem resistance in Pseudomonas aeruginosa–infected patients. Am J Infect Control. 2016;44(11):1275–9.PubMedCrossRef Judd WR, Ratliff PD, Hickson RP, Stephens DM, Kennedy CA. Clinical and economic impact of meropenem resistance in Pseudomonas aeruginosa–infected patients. Am J Infect Control. 2016;44(11):1275–9.PubMedCrossRef
48.
go back to reference Hassuna NA, Darwish MK, Sayed M, Ibrahem RA. Molecular epidemiology and mechanisms of high-level resistance to meropenem and imipenem in Pseudomonas aeruginosa. Infect and Drug Resist. 2020;13:285–93.CrossRef Hassuna NA, Darwish MK, Sayed M, Ibrahem RA. Molecular epidemiology and mechanisms of high-level resistance to meropenem and imipenem in Pseudomonas aeruginosa. Infect and Drug Resist. 2020;13:285–93.CrossRef
49.
go back to reference Rhomberg PR, Jones RN. Summary trends for the meropenem yearly susceptibility test information collection program: a 10-year experience in the United States (1999–2008). Diagn Microbiol Infect Dis. 2009;65(4):414–26.PubMedCrossRef Rhomberg PR, Jones RN. Summary trends for the meropenem yearly susceptibility test information collection program: a 10-year experience in the United States (1999–2008). Diagn Microbiol Infect Dis. 2009;65(4):414–26.PubMedCrossRef
50.
go back to reference Garcia-Rodriguez J, Jones R, Group, Study TMP. Antimicrobial resistance in gram-negative isolates from European intensive care units: data from the Meropenem yearly susceptibility Test Information Collection (MYSTIC) programme. J Chemother. 2002;14(1):25–32.PubMedCrossRef Garcia-Rodriguez J, Jones R, Group, Study TMP. Antimicrobial resistance in gram-negative isolates from European intensive care units: data from the Meropenem yearly susceptibility Test Information Collection (MYSTIC) programme. J Chemother. 2002;14(1):25–32.PubMedCrossRef
51.
go back to reference Labarca JA, Salles MJC, Seas C, Guzmán-Blanco M. Carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter baumannii in the nosocomial setting in Latin America. Crit Rev Microbiol. 2016;42(2):276–92.PubMed Labarca JA, Salles MJC, Seas C, Guzmán-Blanco M. Carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter baumannii in the nosocomial setting in Latin America. Crit Rev Microbiol. 2016;42(2):276–92.PubMed
52.
go back to reference Wang H, Chen M, Ni Y, Liu Y, Sun H, Yu Y, Yu X, Mei Y, Liu M, Sun Z. Antimicrobial resistance among clinical isolates from the Chinese Meropenem Surveillance Study (CMSS), 2003–2008. Int J Antimicrob Agents. 2010;35(3):227–34.PubMedCrossRef Wang H, Chen M, Ni Y, Liu Y, Sun H, Yu Y, Yu X, Mei Y, Liu M, Sun Z. Antimicrobial resistance among clinical isolates from the Chinese Meropenem Surveillance Study (CMSS), 2003–2008. Int J Antimicrob Agents. 2010;35(3):227–34.PubMedCrossRef
53.
go back to reference Arowolo MT, Orababa OQ, Olaitan MO, Osibeluwo BV, Essiet UU, Batholomew OH, Ogunrinde OG, Lagoke OA, Soriwei JD, Ishola OD. Prevalence of carbapenem resistance in Acinetobacter baumannii and Pseudomonas aeruginosa in sub-saharan Africa: a systematic review and meta-analysis. PLoS ONE. 2023;18(11):e0287762.PubMedPubMedCentralCrossRef Arowolo MT, Orababa OQ, Olaitan MO, Osibeluwo BV, Essiet UU, Batholomew OH, Ogunrinde OG, Lagoke OA, Soriwei JD, Ishola OD. Prevalence of carbapenem resistance in Acinetobacter baumannii and Pseudomonas aeruginosa in sub-saharan Africa: a systematic review and meta-analysis. PLoS ONE. 2023;18(11):e0287762.PubMedPubMedCentralCrossRef
54.
go back to reference Ayobami O, Brinkwirth S, Eckmanns T, Markwart R. Antibiotic resistance in hospital-acquired ESKAPE-E infections in low-and lower-middle-income countries: a systematic review and meta-analysis. Emerg Microbes Infections. 2022;11(1):443–51.CrossRef Ayobami O, Brinkwirth S, Eckmanns T, Markwart R. Antibiotic resistance in hospital-acquired ESKAPE-E infections in low-and lower-middle-income countries: a systematic review and meta-analysis. Emerg Microbes Infections. 2022;11(1):443–51.CrossRef
Metadata
Title
Prevalence of meropenem-resistant Pseudomonas Aeruginosa in Ethiopia: a systematic review and meta‑analysis
Authors
Mengistie Yirsaw Gobezie
Minimize Hassen
Nuhamin Alemayehu Tesfaye
Tewodros Solomon
Mulat Belete Demessie
Tesfaye Dessale Kassa
Teklehaimanot Fentie Wendie
Abel Andualem
Ermiyas Alemayehu
Yaschilal Muche Belayneh
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Antimicrobial Resistance & Infection Control / Issue 1/2024
Electronic ISSN: 2047-2994
DOI
https://doi.org/10.1186/s13756-024-01389-2

Other articles of this Issue 1/2024

Antimicrobial Resistance & Infection Control 1/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.